It’s time to treat with
The first and only FDA-approved therapy for Non-24-Hour Sleep-Wake Disorder (Non-24)1
Non-24 is highly prevalent—up to 70%—in people who are
totally blind1,2 Learn more
HETLIOZ® (tasimelteon)—the first and only FDA-approved therapy
for Non-24-Hour Sleep-Wake Disorder (Non-24)3 Learn more
Find out more
References: 1. Sack RL, et al. Sleep Med Rev. 2001;5(3):189-206. 2. Dressman MA, et al. Poster presented at: 26th Annual Meeting of the Associated Professional Sleep Societies, LLC; June 10, 2012; Boston, MA. Poster 49. 3. HETLIOZ® [prescribing information]. Vanda Pharmaceuticals Inc. 2014.
Reference: HETLIOZ® [prescribing information]. Vanda Pharmaceuticals Inc. 2014.
The most common adverse reactions (incidence >5% and at least twice as high on HETLIOZ® (tasimelteon) than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection. The risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ® is increased by approximately 2-fold compared with younger patients.
HETLIOZ® (tasimelteon) capsules are indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in adults and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older. HETLIOZ LQTM oral suspension is indicated for the treatment of nighttime sleep disturbances in SMS in patients 3 to 15 years of age.
Please see full US Prescribing Information.